This substitution at position 19 had previously been revealed to attenuate Gal-8’s capacity as bridging molecule between exosome-like vesicles or as hemagglutinin [36], but to increase the extent of Gal-8-dependent inhibition of tumor cell proliferation [61]. The gene discussed is LGALS8; the disease is neoplasm.